Clinical trial data and emerging strategies: HER2-positive breast cancer
S Pernas, SM Tolaney - Breast Cancer Research and Treatment, 2022 - Springer
Breast Cancer Research and Treatment, 2022•Springer
A deeper insight into tumor biology and HER2 signaling has led to the development of novel
anti-HER2 drugs that have significantly improved the prognosis of patients with HER2-
positive breast cancer. The breast cancer immune microenvironment has emerged as a
potential prognostic factor. Moreover, the host immune system not only seems to play a
critical role in the prognosis of HER2-positive breast cancer, but also seems to modulate
treatment response to some HER2-targeted agents. Here, we review the latest evidence of …
anti-HER2 drugs that have significantly improved the prognosis of patients with HER2-
positive breast cancer. The breast cancer immune microenvironment has emerged as a
potential prognostic factor. Moreover, the host immune system not only seems to play a
critical role in the prognosis of HER2-positive breast cancer, but also seems to modulate
treatment response to some HER2-targeted agents. Here, we review the latest evidence of …
Abstract
A deeper insight into tumor biology and HER2 signaling has led to the development of novel anti-HER2 drugs that have significantly improved the prognosis of patients with HER2-positive breast cancer. The breast cancer immune microenvironment has emerged as a potential prognostic factor. Moreover, the host immune system not only seems to play a critical role in the prognosis of HER2-positive breast cancer, but also seems to modulate treatment response to some HER2-targeted agents. Here, we review the latest evidence of the role of immunotherapy in HER2-positive breast cancer and present emerging strategies.
Springer